Pular para o conteúdo principal
Ranking Invest

AKBA - Akebia Therapeutics, Inc.

Segmento: HealthcareAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Análise Ranking Invest

Valor de Mercado
$ 178.40 Mi
IVR
-0.79Índice proprietário de comparação relativa: -0,79.
IVR2
-0.99Leitura proprietária complementar: -99%.
MLL
-0.99Leitura proprietária complementar: -99%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 25.02 Mi

Dívida Líquida

-$ 105.98 Mi

L4T

-$ 29.67 Mi

MM4T

-13.84%

Indicadores Básicos

ROE

-118.58%

Índices de Previsibilidade

Receita Líquida

E0.14

Lucro

D0.72

Margem

D0.97

Índices de Tendência

Receita Líquida

C3.66

Lucro

C3.22

Margem

B5.81

Índices de Endividamento

DIV/PAT

-4.24

DIV/L4T

3.57

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.